Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million
12 mai 2023 07h00 HE
|
Humacyte, Inc.
- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones,...
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine
09 mai 2023 08h00 HE
|
Humacyte, Inc.
First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09, 2023 (GLOBE NEWSWIRE) --...
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
05 mai 2023 08h00 HE
|
Humacyte, Inc.
DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma
04 mai 2023 08h00 HE
|
Humacyte, Inc.
HAV granted second RMAT designation by the FDARMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a...
Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
28 avr. 2023 08h00 HE
|
Humacyte, Inc.
DURHAM, N.C., April 28, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes
27 avr. 2023 08h00 HE
|
Humacyte, Inc.
NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally...
Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
18 avr. 2023 08h00 HE
|
Humacyte, Inc.
Results published in Journal of Trauma and Acute Care Surgery Company also provides update on enrollment progress in Phase 2/3 vascular trauma trial DURHAM, N.C., April 18, 2023 (GLOBE...
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
11 avr. 2023 08h00 HE
|
Humacyte, Inc.
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
26 août 2021 16h05 HE
|
Humacyte, Inc.
Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021Company well-positioned to deliver on...
Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte
24 août 2021 12h58 HE
|
Humacyte, Inc.
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders...